1. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some
2. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity
3. Nitrosamine impurities https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities#scientific-review-on-the-risk-of-nitrosamine-impurities-in-human-medicines-section
4. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities;Bharate;J Med Chem,2021
5. Nitrosamine impurities in medications: Medications affected https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-affected.html